Aims: Abciximab provides dose-dependent antiplatelet and anti-inflammatory properties. No specifically designed prospective studies have addressed the role of intracoronary bolus administra
NEW ISSUE
Ischaemia with non-obstructive coronary arteries, OCT vs IVUS guidance in PCI; the ILUMIEN III and ILUMIEN IV trials…
January 20, 2021